Compare Standard Lithium Ltd (SLI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Standard Lithium Ltd trades at $2.27 (market cap $523.89M), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SLI | XBI | |
|---|---|---|
Market Cap | $523.89M | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $5.65 | $164.28 |
52-Week Low | $2.15 | $85.16 |
Enterprise Value | $383.09M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
